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Variation in Target Attainment of Beta- Lactam 
Antibiotic Dosing Between International 
Pediatric Formularies
Silke Gastine1, Yingfen Hsia2, Michelle Clements3, Charlotte I.S. Barker4,5, Julia Bielicki5,6, 
Christine Hartmann2, Mike Sharland5 and Joseph F. Standing1,7,*
As antimicrobial susceptibility of common bacterial pathogens decreases, ensuring optimal dosing may preserve 
the use of older antibiotics in order to limit the spread of resistance to newer agents. Beta- lactams represent the 
most widely prescribed antibiotic class, yet most were licensed prior to legislation changes mandating their study 
in children. As a result, significant heterogeneity persists in the pediatric doses used globally, along with quality 
of evidence used to inform dosing. This review summarizes dosing recommendations from the major pediatric 
reference sources and tries to answer the questions: Does beta- lactam dose heterogeneity matter? Does it 
impact pharmacodynamic target attainment? For three important severe clinical infections— pneumonia, sepsis, 
and meningitis— pharmacokinetic models were identified for common for beta- lactam antibiotics. Real- world 
demographics were derived from three multicenter point prevalence surveys. Simulation results were compared 
with minimum inhibitory concentration distributions to inform appropriateness of recommended doses in targeted 
and empiric treatment. While cephalosporin dosing regimens are largely adequate for target attainment, they also 
pose the most risk of neurotoxicity. Our review highlights aminopenicillin, piperacillin, and meropenem doses as 
potentially requiring review/optimization in order to preserve the use of these agents in future.
In a 2020 report on child mortality led by the United Nations 
Children’s Fund (UNICEF) and the World Health Organization 
(WHO),1 infectious diseases were found to be the leading cause 
of death in children under the age of 5 years and are estimated to 
cause over half of deaths in this age group.2 Bacterial infections, 
increasingly involving multidrug resistant organisms, are respon-
sible for a significant proportion of these deaths, with pneumonia 
accounting for 15%, sepsis 7%, and meningitis 2%, respectively.1 
In many cases these infectious diseases are preventable and need to 
be targeted by both policies aimed at prevention and also optimal 
treatment.
One barrier to optimal treatment is the rise of antimicrobial 
resistance (AMR), particularly among gram- negative organ-
isms. Over the last 20 years in Malawi, bloodstream isolates have 
changed from mainly sensitive to mainly resistant to first- line an-
tibiotics (gentamicin, ampicillin, and cefotaxime), with resistance 
in Klebsiella species now over 90%.3 This concerning trend is seen 
throughout other low- income and middle- income countries,2 and 
may mean that previous gains in reductions in mortality may be im-
pacted by infections caused by multidrug resistant organisms.4 In 
an effort to reduce the spread of AMR, the WHO has categorized 
the Essential Medicines List (EML) agents into "Access," "Watch," 
and "Reserve" (AWaRe) antibiotics,5 to manage global antibiotic 
usage. This seeks to limit the use of “Watch” and “Reserve” agents 
where possible. In vitro there is evidence to suggest that low anti-
biotic exposure can select for or induce resistance, whereas when 
concentrations are higher resistance is less likely to appear.6 While 
clinical dosing guidelines should primarily recommend “Access” 
and “Watch” agents, a key aspect of preserving their efficacy is 
therefore to ensure dosing is optimized.
Historically, there were limited antimicrobial studies in children, 
but in 2003 the United States introduced the Best Pharmaceuticals 
for Children Act and the Pediatric Research Equity Act to ensure 
all new agents had to be studied;7 regulators in other territories 
followed suit shortly thereafter. This meant that new antimicro-
bial agents were formally studied— although those studies often lag 
significantly behind adult development.7 Since most antimicrobi-
als in the WHO EML “Access” and “Watch” groups were licensed 
before 2003, inconsistent dosing guidelines are common. By far 
the largest proportion of “Access” and “Watch” agents are the beta- 
lactams, which were licensed prior to these legislative changes and 
therefore variably studied in children.
Recent large global antimicrobial point prevalence surveys 
have confirmed that wide variability in antimicrobial dosing in 
children persists in clinical practice.8 Differences include the 
prescribed doses, frequencies, and in some cases the route of 
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administration. Information on optimal dosing across different 
pediatric age groups is still lacking for many antibiotics and has 
often been omitted from drug labeling information. Formularies 
established by national and international expert groups are one 
of the main resources for pediatric drug dosing guidelines used 
in clinical care. Many of these have recently switched to digital 
platforms in order to increase their instant availability and con-
temporary information.9 Nevertheless, most formularies do not 
include references that informed the stated dosing recommen-
dations. It is currently unclear whether the heterogeneity in in-
ternational dosing guidelines is affecting antibiotic efficacy and 
safety in children, and if so whether certain dosing guidelines 
should be preferred over others.
For treatment to be successful, it is commonly recognized 
that attaining concentrations above a certain critical target is re-
quired.10 The usual pharmacodynamic marker that guides anti-
biotic efficacy is the minimum inhibitory concentration (MIC). 
Based on in vitro studies, the optimal pharmacokinetic target 
in relation to an organism’s MIC has been defined for each an-
tibiotic: fCmax/MIC, ratio of maximal free drug concentration 
to MIC; fAUC/MIC, ratio of the area under the free drug 
concentration- time curve to MIC; f T > MIC, fraction of time of 
the free drug concentration being above the MIC, with the latter 
usually used for beta- lactam antibiotics.11 However, to define a 
drug’s therapeutic window, an assessment of likely efficacy needs 
to be accompanied by an assessment of the proposed dose’s poten-
tial to cause adverse drug reactions. For some antibiotics with nar-
row therapeutic windows such as nephrotoxicity associated with 
aminoglycosides or glycopeptides, these toxicity cutoffs are well 
defined. For the beta- lactams, toxicity thresholds are less well de-
fined, but increasing evidence points towards neurotoxicity possi-
bly becoming dose- limiting, especially when new dosing regimens 
such as continuous infusion dosing are gaining in popularity.12
Focusing on three clinically important severe syndromes— 
pneumonia, sepsis, and meningitis— this review aimed to assess 
variability and appropriateness in pediatric beta- lactam dosing rec-
ommendations for selected WHO AWaRe antibiotics based on the 
assumption that these were severe infections in hospitalized neo-
nates and children. We collated dosing guidance from national and 
international pediatric formularies, searched for the most appro-
priate model for suggested drugs, and simulated target attainment 
in a real- world setting by sampling underlying syndrome- specific 
populations from point prevalence surveys.
METHODS
Choice of beta- lactam antibiotics and pharmacokinetic 
model selection
For pneumonia, sepsis, and meningitis, common beta- lactam antibiotic/
organism (drug/bug) combinations were extracted from the most re-
cent English Surveillance Program For Antimicrobial Utilization And 
Resistance (ESPAUR) Report in 2018– 2019.13 For pneumonia, the anti-
biotics selected were amoxicillin- clavulanate (co- amoxiclav), ampicillin/
sulbactam, and benzylpenicillin (penicillin G). Oral co- amoxiclav was 
also evaluated for step- down treatment. For sepsis the following antibi-
otics were chosen: cefotaxime, ceftazidime, ceftriaxone, co- amoxiclav, 
piperacillin- tazobactam, and meropenem. For meningitis, cefotaxime, 
ceftriaxone, and meropenem were selected.
For each drug a pediatric pharmacokinetic (PK) model was identi-
fied from our recently published systematic review.14 This review sug-
gested an evidence grading based on the data and modeling presented. 
Briefly, a scoring system was developed to rate the conducted PK assess-
ment through the pharmacokinetic- pharmacodynamic (PKPD) dosing 
evidence score. On top of the score, extracted publications were then 
assessed regarding the underlying studies’ quality to derive the overall 
quality- of- evidence rating, which was summarized as strong, interme-
diate, or weak strength of recommendation. The literature search was 
limited to articles published on pediatric PK studies for AWaRe anti-
biotics, and the search was conducted in PubMed. A graphical over-
view of the scoring system can be found in Figure S1. The search was 
repeated for the subsequent time frame May 2018 to October 2020 to 
include more recently published literature.
For the current assessment, PK models were chosen based on their 
quality- of- evidence rating. Where pediatric models were not available, 
adult models were scaled down to pediatric populations by including 
allometric scaling and maturation functions.15– 18 If multiple models of 
the same evidence score were found eligible, a decision was made taking 
size of the modeled cohort, published goodness- of- fit criteria, and the 
included significant covariates available in the point prevalence data 
set into account. For the models designated for our simulations, model 
code was retrieved from the publication’s supplementary information. 
If model code was not published, the authors were contacted to share 
the original code.
Neonatal and pediatric demographic population 
development
Demographics for a population of hypothetical neonates, infants, and 
children with pneumonia, sepsis, and meningitis were then generated. 
Real demographics were sampled using R (version 4.0.2; R foundation 
for statistical computing, Vienna, Austria) from three different data sets: 
a one- day point prevalence survey (PPS) on antibiotic prescription, which 
was collected from the Global Antimicrobial Resistance, Prescribing and 
Efficacy in Neonates and Children (GARPEC) Network;8 the Global 
Point Prevalence Survey on Antimicrobial Consumption and Resistance 
(Global PPS) network;8 and the Antibiotic Resistance and Prescribing 
in European Children (ARPEC) project.19 Patients aged < 19 years re-
ceiving at least one antibiotic on the day of the respective survey were 
included.
In total, 116 hospitals from 26 countries participated in the GARPEC 
PPS between 2015 and 2017. The Global PPS survey, conducted between 
October 2014 and November 2015, included 335 hospitals from 53 coun-
tries. ARPEC was carried out in 18 centers across 11 countries. Patients 
were assigned to pneumonia, sepsis, or meningitis based on the docu-
mented reason for starting antibiotics in the respective survey databases. 
From each data set the demographic covariates age, weight, and sex were 
extracted; for neonates postnatal age and gestational age were extracted 
and postmenstrual age calculated.
The individual patient’s age- dependent typical creatinine concentra-
tion was derived from the equation by Ceriotti et al.20 This method has 
previously been used to model age- adjusted creatinine in PK studies.21– 23 
Typical albumin concentration was calculated based on the patient’s post-
menstrual age in line with previous publications.24,25 The demographics 
derived from the PPS data sets can be seen as real- world cases, and the 
formed subpopulations represent the actual target population for each 
treatment indication.
Systematic search for dosing guidelines
Pediatric formularies were searched to identify the dosing regimens 
for each antibiotic to treat each clinical infection. The following na-
tional and international formularies were chosen, in order to cover 
the range of regimen per drug, that are used globally: British National 
Formulary for Children,26 Dutch/German Database for Pediatric 
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Dosing (Kinderformularium),27 German Pediatric Infectious Diseases 
Society Handbook,28 Swiss Database for Dosing Medicinal Products 
in Pediatrics (SwissPedDose),29 Indian National Center for Disease 
Control guidance,30 Nelson’s Pediatric Antimicrobial Therapy (Bradley 
et al.),31 Manual of Childhood Infections (Blue Book),32 Report of the 
Committee on Infectious Diseases (Red Book),33 and the WHO Pocket 
Book.34
For the three infectious diseases, pneumonia, sepsis, and meningitis, 
dosing guidance was extracted from each formulary. Additionally, the 
minimum and maximum regimen were listed alongside the WHO expert 
consensus regimen5 aiming to display a median regimen across all formu-
laries. Dosing information was collected for the following pediatric age 
groups: neonates (≤ 28 days); infants/children (>28 days– 12 years) and 
adolescents (>12 years).
Pharmacokinetic- pharmacodynamic analysis
Simulations for the chosen drugs’ PKPD relationships were conducted 
from the chosen models using NONMEM 7.4 (version 7.4; ICON 
Development Solutions, Ellicott City, MD). Post- simulation process-
ing and graphical evaluations were performed in R. For pneumonia 
the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) nonspecies- related drug- specific sensitivity and resis-
tance breakpoints were compared with target attainment, whereas for 
sepsis and meningitis the breakpoints for Enterobacterales were used. 
Histograms of some the following example organisms drawn from the 
EUCAST MIC distribution database were displayed for comparison: 
Streptococcus pneumoniae and Staphylococcus aureus for pneumonia 
and Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aerugi-
nosa for sepsis and meningitis. The chosen organism/antibiotic (bug/
drug) combinations and extracted common, minimum, and maxi-
mum dosing recommendations were used to generate probability of 
target attainment (PTA) simulations within the targeted subpopu-
lation by using the PKPD model with the highest level of evidence in 
this setting. The evaluated targets were dependent on the respective 
simulated drugs. Susceptibilities were displayed as MIC distribu-
tions; breakpoints ref lecting sensitive and resistant isolates were de-
rived from the EUCAST database for the respective microorganisms. 
For simulations in each clinical condition 10,000 demographic sets 
were sampled with replacement from the GARPEC / Global PPS / 
ARPEC subpopulation data sets. For clinical markers creatinine, cre-
atinine clearance, and albumin that were derived from age- dependent 
functions, a variance of 10% around the calculated typical values was 
introduced.
Target attainment analysis
Pharmacodynamic (PD) analysis was carried out through PTA as-
sessment from the simulations. Targets were chosen depending on the 
pharmacodynamics of the investigated drug / drug class. As suggested 
by Mouton et al.35 the fraction of time above MIC is seen as the appro-
priate target for beta- lactam antibiotics. Free, unbound concentrations 
were used to evaluate the PKPD target. For ceftriaxone, free concentra-
tion accounting for nonlinear concentration- dependent protein binding 
was assumed.36 For the other agents the following fraction unbound was 
assumed: amoxicillin 83%,37 ampicillin 80%,38 benzylpenicillin 45%,39 
cefotaxime 70%,39 ceftazidime 83%,40 meropenem 98%,37 and piperacil-
lin 70%.37 In line with current guidance for severe hospitalized patients, 
an overall beta- lactam PKPD target of 100% fT > MIC within a 24- hour 
time frame at steady state was chosen.41 Further investigation was per-
formed looking at 50% fT > MIC for less severe infections that can be 
found in the community setting and 100% fT > 4× MIC when a criti-
cally ill population is targeted.42
Results from the target attainment analysis were compared graphically 
and numerically with isolate- specific MIC distributions from EUCAST 
clinical breakpoint reports. For sepsis and meningitis sensitive and 
resistant breakpoints reflecting Enterobacterales were added. In pneumo-
nia nonspecies- related breakpoints were chosen.
Toxicity analysis
For the simulated drug toxicity, cutoffs were extracted from the litera-
ture. A general neurotoxicity threshold of 316 mg/L was used for beta- 
lactams in line with findings by Imani et al.12 For cephalosporins a 
threshold of 35 mg/L, as reported by Huwyler et al.43 for cefepime, was 
chosen. Cefepime is seen as the cephalosporin with the highest risk for 
causing neurotoxicity. Other drug- specific targets reported in literature 
for trough concentrations correlated with a proconvulsive risk that were 




After cleaning and combining the three point- prevalence data sets 
GARPEC, Global PPS and ARPEC, subpopulations that were 
treated for pneumonia, sepsis, and meningitis consisted of 2,932, 
2,269, and 1,358 individuals, respectively, with age ranging from 
23 weeks postmenstrual age to 18 years postnatal age (PNA), and 
weight ranging from 0.31 kg to 95.5 kg.
Figure 1 shows the age- related weight distribution for each sub-
population with an additional panel showing the included neo-
nates. Each graph also shows the typical weight for age distribution 
published for preterm and term neonates by Fenton et al.,44,45 for 
up to 5- year- olds by the WHO46 and for 5- year- olds to 18- year- olds 
by the Centers for Disease Control and Prevention (CDC).47
Dosing regimen
Table S1 summarizes the dosing recommendations for the differ-
ent age groups (from preterm neonates to adolescents) extracted 
from summaries of product charcteristics (SmPCs) and formu-
laries, together with the common, minimum, and maximum 
regimen.
Within the three different infections, pneumonia, sepsis, and 
meningitis, 6/120 (5%), 10/180 (6%), and 40/90 (44%) of the in-
divdual dose recommendations, respectively, were specific recom-
mendations for the evaluated disease. Overall, for 88/390 (23%), 
dosing recommendations were lacking for the respective age group, 
drug, and formulary.
Selected PK models for simulation
The systematic literature search and evidence grading resulted 
in five models with a mean dose evidence score (DES) of 8 (7– 
10). The overall quality of evidence (QoE) was rated strong 
(n  =  2) or intermediate (n  =  3). The beta- lactams benzylpen-
icillin, intravenous co- amoxiclav, piperacillin- tazobactam, ce-
fotaxime, and meropenem were well described by Lonsdale et 
al.15 (DES  =  7, strong QoE) across the entire age range. Oral 
co- amoxiclav was simulated according to the model by deVelde 
et al.48 (DES  =  10, intermediate QoE); ampicillin- sulbactam 
was modeled according to Soto et al.49 (DES = 9, intermediate 
QoE); ceftriaxone according to Standing et al.36 (DES = 10, in-
termediate QoE); and ceftazidime by using the model from Li 
et al.50 (DES = 7, strong QoE). Selected models are summarized 
in Table S3.
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Evaluating probability of target attainment
Common, minimum, and maximum dosing was simulated for 
each drug using the chosen highest evidence models. Figure  2 
shows the target attainment results for pneumonia, Figure  3 
for sepsis, and Figure 4 for meningitis. Dark shaded areas show 
the 90% prediction interval across the simulated subpopulation 
Figure 1 Weight compared with age for the three simulated subpopulations: pneumonia, sepsis, and meningitis. Black dots are single 
subjects filtered from GARPEC / ARPEC / Global PPS. Gray lines represent the median, 3rd, and 97th percentiles from demographic surveys 
by Fenton et al., CDC (Centers for Disease Control and Prevention), and WHO (World Health Organization).
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for the common regimen, with the solid black line showing the 
population mean. Light shaded areas show the prediction inter-
val stretching from the 5th percentile of the minimum dose to the 
95th percentile of the maximum dose. The simulation results were 
explored graphically for each disease against the chosen isolates 
EUCAST MIC distribution through the presentation of colored 
histograms representing the respective isolates distribution. The 
EUCAST sensitive and resistant breakpoints for Enterobacterales 
are shown as solid gray lines within the sepsis and meningitis as-
sessments. For pneumonia the EUCAST nonspecific sensitive and 
resistant breakpoints are shown.
The predicted MIC at which the targets 100% f T > MIC and 
100% f T  >  4× MIC are crossed is reported for each antibiotic 
alongside the EUCAST epidemiological cutoff value and empiric 
target MIC values for the considered isolates (Table S2).
The percentage of patients reaching the 100% f T > MIC PKPD 
target, when sensitive and resistant breakpoints for Enterobacterales 
(sepsis and meningitis) or nonspecies related (pneumonia) are con-
sidered is summarized in Figure 5.
Toxicity
The probability of trough concentrations crossing the literature- 
reported toxicity thresholds is depicted in Figure 6. The trough 
concentration at steady state was evaluated for every individual, 
and the proportion of individuals crossing the threshold is dis-
played. Only the risk of toxicity for the different cephalosporin 
regimens to cross the reported cefepime trough threshold of 
35 mg/L is shown, as other drug classes did not notably exceed the 
toxicity threshold for any of the simulated regimens.
DISCUSSION
In our analysis we focused on commonly used beta- lactam antibi-
otics featuring in the WHO EML for children.5 Point prevalence 
surveys have revealed heterogeneity in dosing across and within 
countries,51 and we found this to be reflected in varying dosing rec-
ommendations provided by national and international formularies.
Due to developmental differences in drug handling (mainly 
lower clearance),52 neonates are usually given lower per- killogram 
doses; hence we split assessment of target attainment between 
neonates and children. Figures 2– 4 show each drug’s PKPD tar-
get attainment trajectory across MIC values for 100%f T > MIC 
in neonates and children. The simulated common dosing regi-
men showed third generation cephalosporin dosing guidelines 
are generally appropriate (Figure  5). Sufficient coverage was 
achieved for ceftriaxone when used in empiric sepsis and menin-
gitis treatment, with at least 90% of the simulated patient pop-
ulation being covered for sensitive Enterobacterales. Cefotaxime 
also showed good coverage in both severe syndromes, yielding 
at least 80% of patients reaching the PKPD target considering 
sensitive Enterobacterales MICs (Figure 5). When MIC targets 
reflecting resistant breakpoints are chosen, ceftriaxone still per-
forms well.
Figure 2 Probability of target attainment (100%fT > MIC) for simulated dosing regimen in the pneumonia subpopulation. Solid line, median 
for common regimen; dark gray area, 90% prediction interval for common regimen; light gray area, 5th percentile of minimal regimen to 
95th percentile of maximal regimen. Colored histograms refer to the MIC distribution for common pathogens Haemophilusinfluenzae (red), 
Streptococcus Pneumoniae (blue) and Staphylococcus aureus (green) according to EUCAST (European Committee on Antimicrobial Susceptibility 
Testing). The gray solid vertical line represents the nonspecies- specific breakpoint values for each drug to guide empiric treatment. fT > MIC, 
fraction of time of the free drug concentration being above the MIC; IV, intravenous; MIC, minimum inhibitory concentration; R, resistant 
breakpoint; S, sensitive breakpoint.
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Considering the resistant breakpoints for Enterobacterales, cef-
tazidime reached at least 70% coverage in sepsis treatment, and 
cefotaxime covered at least 70% of the population for sepsis and 
meningitis, whereas meropenem failed to successfully reach ad-
equate concentrations in both diseases. This is largely due to the 
high empiric MIC cutoff of 2mg/L reflecting the fact that target at-
tainment in settings with borderline carbapenem resistance would 
likely require higher meningitis doses even when treating sepsis and 
the use of an overall beta- lactam PKPD target of 100%f T > MIC. 
Carbapenems show a higher postantibiotic effect compared with 
other beta- lactams. A target of 20%f T > MIC has been shown to 
be bacteriostatic in in vitro models, with 40%f T > MIC resulting 
in bactericidal effects.
While piperacillin- tazobactam also achieved sufficient levels in 
more than 75% of the pediatric population regarding sensitive break-
points (Figure 5), isolate- specific epidemiological cutoff values, rep-
resenting the critical epidemiological MIC that covers all MICs of 
wild- type isolates values, are, however, higher than this nonspecies- 
specific value. Coverage for the resistant Enterobacterales breakpoint 
of 16 mg/L only accounts for 70% (79−46%). A re- analysis of the 
Figure 3 Probability of target attainment (100%fT > MIC) for simulated dosing regimen in the sepsis subpopulation. Solid line, median for 
common regimen; dark gray area, 90% prediction interval for common regimen; light gray area, 5th percentile of minimal regimen to 95th 
percentile of maximal regimen. Colored histograms refer to the MIC distribution for common pathogens Escherichiacoli (red), Klebsiella 
pneumoniae (green), and Pseudomonas aeruginosa (blue) according to EUCAST (European Committee on Antimicrobial Susceptibility Testing). 
The gray solid vertical line represents Enterobacterales breakpoints for each drug to guide empiric treatment. fT > MIC, fraction of time of the 
free drug concentration being above the MIC; MIC, minimum inhibitory concentration; R, resistant breakpoint; S, sensitive breakpoint.
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Figure 4 Probability of target attainment (100%fT > MIC) for simulated dosing regimen in the meningitis subpopulation. Solid line, median 
for common regimen; dark gray area, 90% confidence interval for common regimen; light gray area, 5th percentile of minimal regimen to 
95th percentile of maximal regimen. Colored histograms refer to the MIC distribution for common pathogens Neisseriameningitidis (green), 
Streptococcus pneumoniae (blue) and Escherichiacoli (red) according to EUCAST (European Committee on Antimicrobial Susceptibility Testing). 
The dark gray solid vertical line represents Enterobacterales breakpoints for each drug to guide empiric treatment. fT > MIC, fraction of time of 
the free drug concentration being above the MIC; MIC, minimum inhibitory concentration; R, resistant breakpoint; S, sensitive breakpoint.
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microbiology data from the MERINO trial showed that infection 
with extended- spectrum beta- lactamase organisms, while “sensitive” 
(with MICs below 16  mg/L), were still associated with increased 
mortality,53 with insufficient target attainment a possible cause.
In pneumonia, none of the studied scenarios led to adequate 
coverage when considering target attainment with sensitive 
nonspecies- related MIC values (Figure 5). However, taking com-
monly detected species into account, pneumonia is dominated 
by gram- positive strains like S. aureus and S. pneumoniae, which 
generally show low MICs. When examining the EUCAST MIC 
distributions in Figure 2 describing these two strains plus the gram- 
negative non– type b Haemophilus influenza,54 co- amoxiclav suffi-
ciently covers the gram- positive strains, whereas penicillin G and 
ampicillin- sulbactam cover the median of the simulated population 
at best. When looking at sepsis, EUCAST MIC distributions for 
E. coli and K. pneumoniae are fairly well covered by cephalosporins 
Figure 5 Coverage calculated as percentage of individuals above the PKPD target of 100%fT > MIC for each simulated drug for the three 
different syndromes. Each bar represents the coverage of the common regimen, with the error bar showing results of the minimal to maximal 
simulated regimen. Bars are split up by sensitive and resistant MIC breakpoints for Enterobacteraes (sepsis and meningitis) or nonspecific 
(pneumonia). fT > MIC, fraction of time of the free drug concentration being above the MIC; IV, intravenous; MIC, minimum inhibitory 






















































































































Figure 6 Percentage of subjects above toxicity threshold (>35 mg/L) for cephalosporins and the respective syndrome. Plots are grouped by 
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and meropenem. Pseudomonas, on the other hand, was less sensi-
tive to most of the studied drugs (Figure 3). Pseudomonas gener-
ally causes sepsis in hospitalized immunocompromised children 
and hence in this setting drug choices and combination therapies 
with better Pseudomonas coverage would be more appropriate than 
increasing the doses of the agents discussed here.
Our findings are in line with Hartman et al.,55 who recently re-
viewed the pharmacokinetics and target attainment of antibiotics 
in critically ill children and reported that target attainment in this 
patient group is suboptimal. They found that for highly monitored 
substances like glycopeptides and aminoglycosides, there are a large 
number of publications available. In fact, 41 vancomycin and 53 
gentamicin studies have also been detected in our previous grad-
ing evidence review with a median dose evidence score of 4 (2– 
11) and 3 (1– 10), respectively. For most beta- lactams, however, 
the available information is sparse or completely lacking for chil-
dren, especially when narrowing it down to the critical care setting. 
Throughout the literature, the PKPD adequacy for beta- lactams 
in pediatric patient populations has most commonly been assessed 
using the following targets: penicillins 40– 50%f T > MIC, ceph-
alosporins 50– 70%f T  >  MIC, and carbapenems, which display 
postantibiotic effects 40%f T > MIC.56– 58
A current analysis by van Donge et al.59 evaluated common 
amoxicillin dosing in neonates by simulating these more conser-
vative PKPD targets along with higher 100% f T > MIC or 100% 
f T  >  4× MIC and the probability of reaching neurotoxic expo-
sures. Here, low PKPD targets were well covered with common 
regimens. Higher targets, when a PTA  >  90% was aspired, were 
failed by all regimens, with the highest simulated regimen expect-
ing exposure above the peak plasma concentration (Cmax) toxicity 
threshold of 140 mg/L.
We focused on EUCAST MIC reporting, but empiric treat-
ment decisions are dependent on local resistance patterns and may 
deviate from what is simulated with the nonspecies- related MICs, 
globally. Figures 2– 4 are depicted with common MIC ranges and 
can be used for local dosing regimen design based on local MIC 
distributions. The selection of a PKPD target in antibiotic treat-
ment depends on the severity of the targeted disease, focus of the 
infection, individual patient factors, and local resistance patterns.60 
As beta- lactams show time- dependent bactericidal effects, the frac-
tion of time that the free concentration is above a multiple of the 
MIC should be targeted. For our simulations we focused on an 
overall beta- lactam PKPD target of 100%f T > MIC.
Bactericidal effect for beta- lactam classes is detectable for 
%f T > MIC as low as 40% in carbapenems, and 50– 70% in ceph-
alosporins and penicillins.41 In critical care the 100%f T  >  MIC 
target, however, resulted in favorable outcomes according to the 
defining antibiotic levels in intensive care unit patients (DALI) 
trial.42 The desired PD targets, however, still remain to be eluci-
dated across different routes of administration and patient pop-
ulations.61 The use of continuous infusion regimen, as studied in 
the Beta- Lactam Infusion Group Study (BLING) I- III for adult 
critical care patients, is often not feasible in neonatal and pediatric 
settings, where intravenous accessibility, volumes, and compati-
bilities have to be taken into account when performing infusion 
management.62
Thus, across the heterogenous severity stages, which are seen 
in the simulated syndromes, a PKPD target of 100% f T > MIC 
seems sensible for achieving overall clinical efficacy, with the op-
tion to accept lower coverage between 50 and 100% f T  >  MIC 
(Figures S2– S4) in less severe infections and increasing the target 
to 100% f T  >  4× MIC (Figures  S5– S7) in critically ill patients 
cared for in pediatric intensive care unit and neonatal intensive 
care unit settings. These PKPD targets are used with simulations of 
plasma concentrations as surrogates for the less accessible focuses 
in meningitis and pneumonia, cerebrospinal fluid, and epithelial 
lining fluid. A drug’s ability to cross into these deeper compart-
ments correlates with its physicochemical properties enabling the 
passage through membranes, transporter affinities, and physiolog-
ical conditions that are also influenced by the pathology of infec-
tious disease, such as pH changes and membrane permeabilities.63 
More insight is needed to understand how maturation influences a 
drug’s distribution to the site of infection and the ability of plasma 
concentrations to serve as surrogates for this.
Similarly, our simulation population includes creatinine concen-
trations used as a covariate in some of the selected models, varying 
around the typical age- related value. Our simulations therefore 
represent target attainment overall.
To depict the influence acute kidney injury (AKI) and aug-
mented clearance would have on the performed simulations, we 
assessed models including the creatinine covariate. Simulated 
populations with at least a 50% increase from baseline creatinine, 
in line with the Kidney Disease: Improving Global Outcomes 
(KIDGO) criteria diagnosing AKI,64 and a 50% decrease in cre-
atinine for augmented renal function are given in Figure S8. This 
highlights the corresponding improvement or worsening in target 
attainment with AKI or augmented renal function, respectively.
The formularies used in this review were both national (four 
European, two US, one Indian) and international. The summa-
ries of product charcteristic (SmPC) recommendation for each 
drug was also studied. Despite consulting national experts, it was 
not possible to find pediatric formularies from Brazil, China, the 
Russian Federation, or South Africa that were clearly endorsed 
nationally, which is in line with a previous analysis by Mathur et 
al.9 We therefore acknowledge that the presented dose collection 
is strongly influenced by European and North American dosing 
guidance. The consulted formularies each state dosing recommen-
dations for almost every drug that was selected. However, there 
are gaps regarding age- specific and disease- specific recommen-
dations. The lack of information is most marked for neonates, 
whereas adult information is often used for adolescents and thus 
is available.
A trend in diversity of dosing recommendations, age- banding, 
and weight- based dosing can be found in older drugs like penicillin 
G. For this particular drug, doses are historically stated in "IU" (in-
ternational units) for some countries and "mg" (milligrams) in oth-
ers. For co- amoxiclav, some formularies state volume of a specified 
strength of suspension rather than a drug- specific dose amount. 
This was also found for the other fixed- combination beta- lactam 
and beta- lactamase inhibitor preparations, where it is not always 
clearly stated whether the dose amounts in the formularies refer to 
the beta- lactam component or the combination.
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Through our previous study to grade evidence in pediatric an-
tibiotic PK reporting,14,65 supplemented by an updated literature 
search, we identified the models used in the target attainment 
simulations. All models used in the simulations were rated with a 
dose evidence score between 7 and 10, with 12 being the maximal 
achievable score. The overall quality of evidence was rated strong 
or intermediate, with intermediate rating rather than strong due 
to most studies being conducted in a single- center setting, with-
out additional data for validation. A key criterion for choosing ap-
propriate models was that covariate parameterization allowed for 
extrapolation across the neonatal and pediatric age range, which 
is often not possible for models developed in subpopulations with 
empirical covariate structures.66
Models that are scalable across the entire pediatric age range are 
still lacking for many antibiotics. For beta- lactams a recent study 
by Lonsdale et al.15 developed a maturation function that is able to 
describe the maturation of the mostly renal clearance mechanisms 
in beta- lactams from neonates to elderly patients. For other drug 
classes similar investigations are still missing. In adults, PK studies 
on antibiotics have recently focused increasingly on determining 
elimination and distribution mechanisms in the disease and syn-
drome specific context. Many adult PK studies are investigating 
specific patient subpopulations with, for example, pneumonia or 
intra- abdominal infections, and exploring the effects of supportive 
therapies, such as dialysis or extra corporeal membrane oxygen-
ation, on PK.
A limitation of our work is that we did not consider subpopu-
lations of the pediatric group. In pediatrics, special subpopulation 
PK is still not well characterized, as is the PK for most fragile pe-
diatric subpopulation of preterms, neonates, and the influence of 
prematurity for low and very- low birthweight neonates.67,68 The 
influence of nutritional status is also lacking for most PK studies 
conducted in pediatrics, but is important to inform dosing deci-
sions when treating infections in underweight and malnourished 
children.69,70,71 Children treated in intensive care, and particularly 
those requiring renal replacement therapy and extra corporeal 
membrane oxygenation, may need altered dosing.72,73
The evaluated toxicity simulations show that for the cephalo-
sporins, the increased meningitis dosing may be associated with an 
increased risk of neurotoxicity (Figure 5). Apart from cephalospo-
rins, other drug classes did not show the risk of neurotoxicity in the 
studied scenarios and were therefore not reported in the graphic. 
Beta- lactam neurotoxicity is not well studied and is difficult to dis-
tinguish from other neurological symptoms that can occur when 
treating infectious disease syndromes like bacterial meningitis. In 
the literature, mostly case reports are available. Imani et al.12 ret-
rospectively evaluated beta- lactam concentration– toxicity rela-
tionships through regression analysis, concluding that penicillins 
like piperacillin show neurotoxicity at trough concentrations as 
high as 361  mg/L. Animal studies report trough concentrations 
at 157 mg/L for piperacillin and 64 mg/L for meropenem toxic-
ity.74 These targets were not or only barely (piperacillin) reached 
with the simulated carbapenems and penicillins. For cephalospo-
rins, cefepime is seen as the most neurotoxic drug and therefore 
is studied more intensively compared with other drugs in this 
group. A threshold trough concentration of 35 mg/L is reported 
as threshold by Huwyler et al.43 and served as reference concen-
tration for this analysis. It is anticipated that other cephalosporins 
bear lower risks of neurotoxicity. So far case reports dominate neu-
rotoxicity reporting for cephalosporins other than cefepime, and 
thus the cefepime neurotoxic threshold serves as a surrogate for a 
regimen’s neurotoxic potential in this review. When treating severe 
infections involving organisms with high MICs, the potential risk 
of neurotoxicity needs to be balanced with treatment success and 
resistance suppression. For example, treating Pseudomonas infec-
tions using ceftazidime with a target of 100% f T > 4× MIC will 
result in an optimal trough exposure of 32 mg/L to cover resistant 
strain MICs of 8 mg/L. This highlights the need of antibiotic stew-
ardship to consider personalized dosing based on patient and or-
ganism considerations.
Renal failure and drug accumulation due to impairment in the 
dominant elimination pathway is one of the main risk factors for 
beta- lactam neurotoxicity. Findings for meropenem and piperacil-
lin/tazobactam that relate free plasma trough concentration to the 
high Pseudomonas breakpoints suggest that minimal free drug con-
centration (fCmin) above eight times the MIC will result in a less 
favorable risk– benefit ratio. This highlights the need to maintain 
a balance of sufficient exposure while avoiding unnecessarily high 
concentrations.
Overall, our review focused on beta- lactam dosing on the WHO 
Essential Medicines List for Children (EMLc) Access and Watch 
antibiotic list. We aimed to find recommendations across the entire 
age range and thus did not choose antibiotics such as tetracycline 
or quinolones, which are not recommended in younger children 
and neonates due to their negative effects on joint, teeth, and liga-
ment development. We also did not evaluate glycopeptides or ami-
noglycosides, as therapeutic drug monitoring is standard practice, 
and these classes are already thoroughly studied.
CONCLUSION
The results of this review demonstrate that the high variability 
of dosing recommendations in national and international formu-
laries impacts PKPD target attainment. While to some this may 
seem unsurprising, since beta- lactams are generally thought to be 
drugs with a large therapeutic window, commonly used dosing 
schemes could routinely be set so high that variability does not 
in fact impact target attainment. However, a combination of in-
creasing resistance and therefore MICs, and the often lack of reg-
ulatory licensing studies to set pediatric dosing, increasingly mean 
that choosing which guideline to follow is important, and should 
be informed by local sensitivity patterns and disease severity in the 
individual or population to be treated.
Pneumonia treatments show adequate target attainment in com-
mon gram- positive infections. Here, co- amoxiclav showed the best 
coverage across all extracted recommendations. Common regimens 
for cephalosporins in the treatment of sepsis and meningitis cover 
sensitive Enterobacterales infections reasonably well, and although 
more than 75% of the pediatric population is adequately covered 
in some instances, this leaves a small but significant proportion 
who are not. For intermediate- to- resistant MICs, Enterobacterales 
infections are covered in just over half of the population when 
using cephalosporins, with even lower target attainment for the 
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penicillins and meropenem. Given that piperacillin- tazobactam 
and meropenem are less likely to cause neurotoxicity than the 
cephalosporins, this suggests the need for reviewing current dos-
ing recommendations in settings where MICs are typically in the 
intermediate range. The data presented here suggest that a “one- 
size- fits- all” dosing recommendation may not be optimal in future 
and local dosing guidelines of AWaRe antibiotics may indeed be 
warranted to reflect variation in AMR patterns globally.
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